ARTERIAL HYPERTENSION AND CHRONIC KIDNEY DISEASE
DOI:
https://doi.org/10.55640/Keywords:
arterial hypertension, chronic kidney disease, glomerular filtration rate, arterial stiffness, cardiovascular risk, pulmonary hypertension.Abstract
Arterial hypertension is both the cause and the result of the progression of chronic kidney disease, which affects about 10-15% of the global population. As the glomerular filtration rate decreases, the blood pressure level increases naturally. Arterial hypertension (AH) and chronic kidney disease (CKD) are independent and well-known risk factors for the development of cardiovascular diseases, and their combination significantly increases the incidence and mortality from cardiovascular pathology. Blood pressure control is an essential factor in slowing the progression of CKD and reducing cardiovascular risk. Patients with hypertension and CKD need combined drug therapy. A number of modern drugs have additional cardio- and nephroprotective properties and should be considered as the first line of therapy. A personalized approach based on evidence-based principles makes it possible to achieve blood pressure control, reducing cardiovascular risk and slowing the progression of CKD.
Downloads
References
1. Mills KT, Xu Y, Zhang W, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int 2015; 88: 950–957. https://doi.org/10.1038/ki.2015.230
2. Хроническая болезнь почек (ХБП). Клинические рекомендации МЗ РФ 2021, https://cr.minzdrav.gov.ru/recomend/469_2
3. Levin A, Stevens PE, Bilous RW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150. https://doi.org/10.1038/kisup.2012.73
4. Артериальная гипертензия у взрослых. Клинические рекомендации МЗ РФ. 2020, https://cr.minzdrav.gov.ru/schema/62_2.
5. Чазова ИЕ, Жернакова ЮВ. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии 2019;16:6-31. https://doi.org/10.26442/2075082X.2019.1.190179
6. Converse Jr RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912–1918. https://doi.org/10.1056/NEJM199212313272704
7. Koomans HA, Roos JC, Boer P, et al. Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 1982; 4: 190–197. https://doi.org/10.1161/01.HYP.4.2.190
8. Dhaun N, Goddard J, Webb D. The endothelin system and its antagonism in chronic kidney disease. J Am
Soc Nephrol 2006; 17:943–955. https://doi.org/10.1681/ASN.2005121256
9. Townsend RR, Wimmer NJ, Chirinos JA, et al. Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens 2010; 23:282–289. https://doi.org/10.1038/ajh.2009.240
10. Kim ED, Tanaka H, Ballew SH, et al. Associations between kidney disease measures and regional pulse wave velocity in a large community-based cohort: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 2018; 72:682–690. https://doi.org/10.1053/j.ajkd.2018.04.018
11. Чазова ИЕ, Жернакова ЮВ. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии 2019;16:6-31. https://doi.org/10.26442/2075082X.2019.1.190179
12. Чихладзе НМ. Артериальная гипертония при хронических заболеваниях почек. In: Симпоматические (вторичные) артериальные гипертонии. 2018, pp. 86–122.
13. Masuda T, Nagata D. Recent advances in the management of secondary hypertension: chronic kidney disease. Hypertens Res 2020; 43: 869–875. https://doi.org/10.1038/s41440-020-0491-4
14. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Nephrol Dial 2021; 23:9–121. https://doi.org/10.28996/2618-9801-2021-2suppl-9-121
15. Thenappan T. Pulmonary hypertension in chronic kidney disease: a hemodynamic characterization. Pulmonary Circulation 2017; 7:567–568. https://doi.org/10.1177/2045893217728462
16. Zabetian A, Sanchez IM, Narayan KMV, et al. Global rural diabetes prevalence: A systematic review and meta-analysis covering 1990–2012. Diabetes Res Clin Pract 2014; 104: 206–213. https://doi.org/10.1016/j.diabres.2014.01.005
17. Beckett NS, Peters R, Fletcher AE, et al. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358:1887–1898. https://doi.org/10.1056/NEJMoa0801369
18. Bhandari S, Ives N, Brettell EA, et al. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrol Dial Transplant 2016; 31:255–261. https://doi.org/10.1093/ndt/gfv346
2009; 54: 113–119. https://doi.org/10.1161/HYPERTENSIONAHA.109.132670
19. Taylor DM, Fraser S, Dudley C, et al. Health literacy and patient outcomes in chronic kidney disease: a
systematic review. Nephrol Dial Transplant 2018; 33: 1545–1558. https://doi.org/10.1093/ndt/gfx293
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India
